{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:46:10Z","timestamp":1792143970963,"version":"4.4.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":280,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess real-world adherence to folic acid (FA) supplementation with methotrexate (MTX) and patient perceptions of a simplified, same-day dosing strategy in RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional online survey co-designed with patient representatives and distributed by the French patient association AFPric. RA patients treated with MTX were eligible. The questionnaire captured MTX and FA regimens, omissions, adverse events and attitudes toward same-day MTX and FA administration. Analyses were descriptive with prespecified subgroup comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 967 respondents (86.8% women; mean age 62.4\u2009years), 86.7% reported once-weekly FA supplementation. Overall, 25.5% reported at least occasional FA omission, with omissions more frequent among long-term MTX users. Nausea after MTX was reported by 46.6% of respondents and by 52.6% of those reporting FA omissions. A same-day MTX and FA regimen was perceived as simpler by 30.5% and 41.5% believed it could reduce FA omission. Overall, 64.8% indicated that they would be willing to participate in a randomised controlled trial evaluating simultaneous administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>One in four people with RA treated with MTX reported FA omissions. Many respondents believed that a same-day regimen could reduce FA omissions, and interest in participating in a clinical trial was high. These findings support the feasibility of prospectively evaluating whether same-day MTX and FA administration may improve adherence and tolerability in selected patients, particularly those receiving once-weekly FA supplementation, without compromising MTX effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rap\/rkag109","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:50:32Z","timestamp":1791460232000},"source":"Crossref","is-referenced-by-count":0,"title":["Patient perspectives on simultaneous methotrexate\u2013folic acid intake to improve adherence in rheumatoid arthritis: a cross-sectional survey"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1848-8847","authenticated-orcid":false,"given":"Elisa","family":"Dalix","sequence":"first","affiliation":[{"name":"SAINBIOSE U1059, University of Jean Monnet Saint-Etienne, Mines Saint-Etienne, INSERM , Saint-Etienne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u00efma","family":"Hamamouche","sequence":"additional","affiliation":[{"name":"Sano\u00efa, e-Health Services , Aubagne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ir\u00e8ne Pico","family":"Philippe","sequence":"additional","affiliation":[{"name":"AFPric (Association Fran\u00e7aise des Polyarthritiques et des Rhumatismes Inflammatoires Chroniques) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Rollot","sequence":"additional","affiliation":[{"name":"AFPric (Association Fran\u00e7aise des Polyarthritiques et des Rhumatismes Inflammatoires Chroniques) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1177-9497","authenticated-orcid":false,"given":"Hubert","family":"Marotte","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, SAINBIOSE U1059, University of Jean Monnet Saint-Etienne, CHU Saint-Etienne, Mines Saint-Etienne, INSERM , Saint-Etienne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026101605072333000_rkag109-B1","author":"World Health Organization"},{"key":"2026101605072333000_rkag109-B2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026101605072333000_rkag109-B3","doi-asserted-by":"publisher","first-page":"105790","DOI":"10.1016\/j.jbspin.2024.105790","article-title":"2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis","volume":"91","author":"Fautrel","year":"2024","journal-title":"Joint Bone Spine"},{"key":"2026101605072333000_rkag109-B4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/rheumatology\/kep366","article-title":"The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review","volume":"49","author":"Westlake","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2026101605072333000_rkag109-B5","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"2026101605072333000_rkag109-B6","doi-asserted-by":"publisher","first-page":"105602","DOI":"10.1016\/j.jbspin.2023.105602","article-title":"Methotrexate also improves rheumatoid arthritis through correction of microbiota dysbiosis","volume":"90","author":"Berthelot","year":"2023","journal-title":"Joint Bone Spine"},{"key":"2026101605072333000_rkag109-B7","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/rheumatology\/keac579","article-title":"Similar effect of co-administration of methotrexate and folic acid for the treatment of arthritis compared to separate administration","volume":"62","author":"Dalix","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026101605072333000_rkag109-B8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2015.02.009","article-title":"Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen cohort","volume":"45","author":"M\u00fcller","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2026101605072333000_rkag109-B9","doi-asserted-by":"publisher","first-page":"E515","DOI":"10.3390\/jcm8040515","article-title":"How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient?\u2014MTX in the treat-to-target strategy","volume":"8","author":"Taylor","year":"2019","journal-title":"J Clin Med"},{"key":"2026101605072333000_rkag109-B10","first-page":"S95","article-title":"Side effects and management of side effects of methotrexate in rheumatoid arthritis","volume":"28","author":"Albrecht","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2026101605072333000_rkag109-B11","doi-asserted-by":"publisher","first-page":"CD000951","DOI":"10.1002\/14651858.CD000951.pub2","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"2013","author":"Shea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026101605072333000_rkag109-B12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7\u2009&lt;\u20091515::AID-ART273\u2009&gt;\u20093.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2026101605072333000_rkag109-B13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026101605072333000_rkag109-B14","doi-asserted-by":"publisher","first-page":"keaf522","DOI":"10.1093\/rheumatology\/keaf522","article-title":"The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs","volume":"65","author":"Bechman","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"2026101605072333000_rkag109-B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/mr\/road098","article-title":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: secondary publication","volume":"34","author":"Kameda","year":"2023","journal-title":"Mod Rheumatol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkag109\/71718180\/rkag109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/4\/rkag109\/71718180\/rkag109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/4\/rkag109\/71718180\/rkag109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:07:30Z","timestamp":1792141650000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkag109\/8885540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9,21]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkag109","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rkag109"}}